



mgc pharma 

Cimetra™ by MGC—a Revolution in Fighting the COVID-19 Pandemic (IP Protected)

October 2021

Disclaimer



The information contained in this presentation and any accompanying oral presentation ("Presentation") is being supplied to you by MGC Pharmaceuticals Limited on behalf of itself and its subsidiaries (together, "MGC"). By accepting this Presentation, you agree to be bound by the following terms.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).

This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with MGC's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of MGC nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.

This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.

This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as "Relevant Persons"). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in MGC is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

No Liability

The information contained in this Presentation has been prepared in good faith by MGC, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including MGC and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, MGC and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any

and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

MGC, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Forward looking statements

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects MGC's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, MGC disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.

Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MGC's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of MGC only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning MGC and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.

This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify MGC for any loss or damage incurred as a result of your breach of this undertaking.

COVID-19 Pandemic – Clinical Challenges



Rapid clinical deterioration in multiple mild and moderate COVID-19 cases



Acute need for fast and massive extension of medical facilities and staffing, especially for ICU wards



Wide extension of social services and governmental support for patients who survived severe and critical forms of COVID-19



High mortality rate linked to ARDS




Lack of effective treatment protocols for mild and moderate cases in community healthcare



COVID-19 Related Cytokine Storm



- Cytokine Storm has been identified as a main reason for mortality in COVID-19 patients.
- The Severe Acute Respiratory Syndrome coronavirus, associated coronavirus disease 2019 (COVID-19) is a syndrome of viral replication in concert with a host inflammatory response.
- Systemic pro-inflammatory Cytokines and Biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with lower chances of survival.



Early Prevention of COVID-19 Cytokine Storm



Cytokine Storm Early Prevention appears to be an effective method of treatment in mild and moderate COVID-19 cases

Use of existing Cytokine Storm Prevention protocols comes with:



High treatment costs



Administration (requires long hospitalisation and trained medical staff)



Potential serious side effects



CimetrA™ – A New Investigational Drug by MGC Pharma



The Drug



- Compounds – combination of Curcumin and Boswellia Serrata
- Administration – Medical oral spray
- Mechanism of action – Immunomodulation in inflammatory conditions
- Delivery System – GraftBio™ SNEDDS
- Administrated twice a day for 2 days
- Dose – 2 ml per day
- Storage conditions – refrigerate
- Treatment cost - ~US100 RRP with no additional clinical costs


Target Market



- Over 230m COVID-19 cases worldwide
- Over 4.8m deaths worldwide
- The average cost of COVID-19 hospital stays in the US is \$40,000¹
- Meaning for every 1,000 patients you keep out of hospital you save \$40m and countless lives
- Healthcare workers say they need more tools to treat people before they are so sick and in need of oxygen



Powered by




1. www.healthcarefinancenews.com/news/average-cost-hospital-care-covid-19-ranges-51000-78000-based-age

MGC Pharma's Regulatory Strategy for CimetrA™



- Pre-clinical Studies according to the FDA requirements – In-Vivo (mice and rats) and In-Vitro (toxicity, safety, efficacy) – Proof of concept (performed in Israel, ended Sep 2020 and August 2021)
- Clinical – Phase II Study (performed in three hospitals in Israel and one hospital in India, ended Nov 2020)
- Clinical – Phase IIa Study (performed in India, ended June 2021)
- Clinical – Phase 3 Study started in Israel July 2021 and ongoing
- For later stage Clinical Trials, in addition to Israel, MGC will perform studies in other countries in South America, East Asia and Eastern Europe. Preliminary contacts have already been initiated
- **CimetrA™** is currently in early stages of approval as an IMP (Investigational Medicinal Product) and under Emergency Use in USA, India, and several Eastern European countries



Pre-Clinical Study of CimetrA™



- Managed according to the FDA standards in GLP Science in Action Preclinical Lab, Ness Ziona, Israel
- Included three phases :
 - In Vitro PBMCs Viability Study
 - In Vitro Mechanism of Action Study on Cytokines induced tissue
 - In Vivo acute Tox Study (elevated dose, 4 study groups – 3 treatment doses and control)
 - Mice Cytokines Storm model



Pre-Clinical Study: General Results



1

CimetrA™ does not affect cell death rate in the PBMC culture

2

CimetrA™ found to be effective in the prevention of the COVID-19 related Cytokines production in the induced tissue

3

In Vivo Acute Tox study showed no abnormalities in animals treated with **CimetrA™**



Clinical Study of CimetrA™



Randomised Placebo-Controlled Clinical Trial



50 patients: 33 in treatment group; 17 in placebo group



COVID-19 positive hospitalised patients in moderate condition



14 days of follow up

Study sites:

- Rambam Medical Center, Israel
- Hillel Yaffeh Medical Center, Israel
- EMMS Medical Center, Israel
- University of Mumbai Hospital, India

Clinical Study: General Results



1

Full recovery of patients in Treatment group vs. very low progress in the Placebo group (**p<0.04**)

2

Reduced %, and duration in the need for supplemental oxygen in the Treatment group vs. Placebo group

3

No mortality in Treatment group vs one case in Placebo group

4

No ICU admission in Treatment group vs. two cases in Placebo group

5

No mechanical ventilation in Treatment group vs. two cases in Placebo group


6

No **Cimetra™** related side effects

Clinical Study: General Results



- **100% success** in “Time to clinical improvement” based on the national Early Warning Score 2 (NEWS2) of ≤ 2 Maintained for 24 hours in comparison to routine treatment
- NEWS Score 2 is the National Early Warning Score (NEWS), by the FDA, which advocates a system to standardise the assessment and response to acute illness



| Study Visit | Study Group | NEWS Score | P |
|------------------|-------------|---------------|-------------|
| Before Treatment | Artemic™ | 1.5152 | 0.54 |
| | Placebo | 1.8824 | |
| Day 15 | Artemic™ | 0.5152 | 0.04 |
| | Placebo | 2.2353 | |

Benefits of Using CimetrA™ in Community




CimetrA™ could be easily used in community clinics and by home-staying patients: oral spray administration does not require trained medical personnel or facilities



Use of **CimetrA™** on early stages in mild-moderate COVID-19 cases (home-staying patients) could save millions of dollars to healthcare providers by preventing multiple hospitalisations and ICU care spending costs and avoid healthcare system collapse



Early prevention of deterioration in mild-moderate COVID-19 cases provided by **CimetrA™** will be effective for savings in governmental social services and insurance companies spending costs for post-COVID rehabilitation of incapacitated COVID-19 survivors



CimetrA™: Summary

- **CimetrA™** is affordable, safe and effective agent in mild and moderate COVID-19 cases in order to prevent clinical deterioration
- Simple Oral Administration: no medical personnel required
- Wide use in community and hospitals
- Cost-efficient solution for healthcare providers and governments
- Possible wide spectrum of further use in inflammatory conditions – GI diseases, chemotherapy treatment patients, autoimmune diseases, flu and pneumonia
- IP Protected by MGC Pharma SIPO P-202100096





mgc pharma



<https://mgcpharma.com.au/>



@mgcpharmaceuticals



@MGC_Pharma



MGC Pharmaceuticals Ltd

UK PR – Tavistock

Charles Vivian +44 20 7920 3150

Charles.Vivian@tavistock.co.uk